Vitamin B3 ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 65 | 原発性免疫不全症候群 | 1 |
| 107 | 若年性特発性関節炎 | 2 |
65. 原発性免疫不全症候群
臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03962114 (ClinicalTrials.gov) | March 18, 2019 | 11/4/2019 | Effects of Vitamin B3 in Patients With Ataxia Telangiectasia | Effects of Nicotinamide Riboside (Vitamin B3) in Patients With Ataxia Telangiectasia. | Ataxia Telangiectasia;ATM Gene Mutation | Dietary Supplement: Vitamin B3 | Radboud University | A-T childrens project;Twan foundation | Enrolling by invitation | 2 Years | N/A | All | 24 | Phase 2 | Netherlands |
107. 若年性特発性関節炎
臨床試験数 : 441 / 薬物数 : 282 - (DrugBank : 56) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-002245-11-NL (EUCTR) | 16/01/2019 | 20/08/2018 | A study to investigate Vitamin B3 concentrations in the joint after intake | Assessing penetration of high dose Nicotinamide (Vitamin B3) in synovial fluid - B-Vit in the joint | Juvenile Idiopathic Arthritis (JIA);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: nicotinamide Product Code: 98-92-0 INN or Proposed INN: NICOTINAMIDE Other descriptive name: Vitamin B3 | UMC Utrecht | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 6 | Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Netherlands | ||
| 2 | EUCTR2016-003643-10-NL (EUCTR) | 14/09/2017 | A study to investigate the safety of additional treatment with Vitamin B3 in children with Juvenile Idiopathic Arthritis (JIA) | Modulating regulatory T cell function in JIA with Vitamin B3 (nicotinamide) treatment - B-Vit in JIA | Juvenile idiopathic arthritis (JIA);Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: nicotinamide Product Code: 98-92-0 | UMC Utrecht | NULL | NA | Female: yes Male: yes | Phase 1;Phase 2 | Netherlands |